PosterSessionOnline

EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER

SLD Summit 2025

23-25 January, Estoril

N. Poster

Poster title

Applicant name

Status


1-PO7	Efficacy of essential phospholipids in reducing hepatic steatosis in patients with different stages of metabolic dysfunction-associated steatotic liver disease A phase IV study	Norbert Stefan	Received

1-PO3	Association between sarcopenia and coronary atherosclerosis in metabolic dysfunction-associated steatotic liver disease	Yeonjung Ha	Received

1-PO6	Muscle composition predicts adverse outcomes in chronic liver disease: A 5-year follow-up study	Wile Balkhed	Received

1-PO4	The impact of cardiopulmonary fitness on MASLD in a combined lifestyle intervention for adolescents with obesity	Maarten Buytaert	Received

1-PO2	Microvascular complications of type 2 diabetes mellitus in patients with concomitant metabolic dysfunction-associated steatotic liver disease in primary care, a prospective cohort study	Martin Bergram	Received

1-PO1	Comparison of transient elastography and shear wave elastography in patients with MAFLD: A single-center experience	Ahmed El Fayoumi	Received

1-PO5	PDE4 inhibition mitigates metabolic-associated steatotic liver disease by reducing lipogenesis and enhancing triglyceride secretion in obese mice	da Silva Hellen	Received

2-PO4	Distinct roles of hepatic S100A10 and S100A11 in metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma	Etienne Delangre	Received

2-PO3	Evaluation of long-term changes in liver function and structure in patients exposed to SARS-CoV-2 infection: a prospective study	Erkin Saeed Saifi	Received

2-PO1	Fibrinolytic activity of blood plasma in pregnant women with MASH against various degrees of obesity	Lina Bahniy	Received

2-PO5	Morphological changes in liver cirrhosis on imaging and associations to clinical parameters, liver stiffness, steatosis and etiology	signe swerkersson	Received

2-PO6	Insulin resistance and sarcopenia in patients with MASLD: Is there a relationship?	Kateryna Pivtorak	Received

2-PO2	Relationship between endothelial dysfunction and metabolic dysfunction-associated steatotic liver disease	Kateryna Pivtorak	Received

3-PO3	The mechanisms of metabolic dysfunction-associated steatotic liver disease(MASLD) development: what can we learn from a MASLD-resistant porcine model?	Miranda Dosi	Received

3-PO4	The effect of obesity and hepatic steatosis on the course and outcomes of COVID 19-associated pneumonia in patients with metabolic dysfunction-associated steatotic liver disease	Taisiia Turankova	Received

3-PO7	Association of cardiometabolic risk and phenotypic age with the course of metabolic dysfunction-associated steatotic liver disease	Anastasiia Radchenko	Received

3-PO5	Exposure to the environmental Bisphenol A influences trained immunity-related pathways in metabolic dysfunction-associated steatotic liver disease (MASLD): A preliminary observation	Marcello Dallio	Received

3-PO1	The dietitians role in the pre-operative workup for patients undergoing laparoscopic surgery of the upper GIT	Mico Price	Received

3-PO6	Rural-urban differentials in health literacy of metabolic dysfunction-associated steatotic liver disease	Varathpavee Bhuriveth	Received

3-PO2	Digital communication intervention and weight loss in patients with metabolic dysfunction-associated steatotic liver disease: A randomised controlled Study	Sakkarin Chirapongsathorn	Received

4-PO6	Modest alcohol consumption influences on the spectrum of bile acids in individuals with intact liver function, resembling the changes in patients with MASLD	Olena Barabanchyk	Received

4-PO5	Prevalence and health literacy of metabolic dysfunction-associated steatotic liver disease and its associated factors in a rural area: a cross-sectional study	Varathpavee Bhuriveth	Received

4-PO3	From MAFLD to MASLD: a real-life head-to-head comparison of MAFLD and MASLD criteria in estimating liver disease progression risk in not-lean and lean subjects	Fiammetta Di Nardo	Received

4-PO1	FLAME model: validation of a tool incorporating alpha-glutathione-s-transferase serum levels for predicting advanced fibrosis and cardiovascular events in MASLD	Mario Romeo	Received

4-PO4	Prevalence of MASLD and its association with the consumption of sugar sweetened beverages among a non-communicable disease cohort in the rural district of Iringa, Tanzania	VALENTIN CALVEZ	Received

4-PO7	Advanced fibrosis affects quality of life and muscle function in patients with metabolic-dysfunction associated steatotic liver disease	Pinelopi Manousou	Received

4-PO2	MASLD and fibrosis status in patients with type 2 diabetes treated at internal medicine clinics: Türkiye DAHUDER awareness of steatotic liver disease (TR-DASLD) study	yasin &351;ahintürk	Received

5-PO3	Advanced unbiased proteomics reveals new molecular mechanisms in steatotic liver disease	Elena Bonzón Kulichenko	Received

5-PO2	Differences in gut microbiome diversity in patients with metabolic dysfunction-associated steatotic liver disease associate with response to faecal microbiota transplant	pinelopi manousou	Received

5-PO6	Predictive factors for hepatocellular carcinoma development in patients with metabolic-dysfunction-associated steatotic liver disease with or without cirrhosis	Pinelopi Manousou	Received

5-PO1	Cholesterol exacerbates the pathophysiology of metabolic dysfunction-associated steatohepatitis by upregulating Hypoxia-Inducible Factor 1 and modulating microcirculatory dysfunction	Evelyn Pereira	Received

5-PO7	Therapeutic potential and safety profiles of resmetirom in the treatment of non-alcoholic steatohepatitis: a systematic review and meta-analysis	Varathpavee Bhuriveth	Received

5-PO5	The pan-PPAR agonist lanifibranor improves liver inflammation, ballooning, and fibrosis in a diet-induced obese MASH hamster model of binge drinking	FRANCOIS BRIAND	Received

5-PO4	A prove-of-concept study of pioglitazone low dose vs standard dose for the treatment of metabolic dysfunction-associated steatohepatitis	Sakkarin Chirapongsathorn	Received

6-PO7	Enhancing trial recruitment in MetALD and ALD with LiverPRO to detect fibrosis	Katrine Lindvig	Received

6-PO4	Multidisciplinary management combining hepatologist counseling, cognitive/behavioral therapy, and nutritional support (the CoCoNut protocol) improves the clinical outcomes of MASLD patients	Marcello Dallio	Received

6-PO1	Normal fibrosis-4 values do not exclude advanced fibrosis in 15 of patients with metabolic dysfunction-associated steatotic liver disease	Pinelopi Manousou	Received

6-PO6	Inter-observer variability of liver biopsy reading in clinical trials for metabolic dysfunction-associated steatohepatitis: A monocentric experience	Sebastiano Archilei	Received

6-PO5	A targeted steroidomic approach to investigate the impact of sexual dimorphism on liver damage in patients with metabolic-dysfunction associated steatotic liver disease	Eleonora Dileo	Received

6-PO3	The impact of diabetes mellitus and glucagon-like peptide-1 agonists on frailty for patients with advanced chronic liver disease	Matthew McKenna-Barry	Received

7-PO2	Fibrosis stage versus fibrosis-4 score for predicting clinical outcomes in metabolic dysfunction-associated steatotic liver disease, and evaluation of healthcare resource utilization and associated costs	Hannes Hagström	Received

7-PO4	Circulating EV-miRs for the diagnosis and staging of MASLD and hepatocellular carcinoma	Santiago Iturbe-Rey	Received

7-PO7	Modeling metabolic-dysfunction associated steatotic liver disease in juvenile zebrafish: a novel platform for disease study and drug discovery	Helena Sarret Casellas	Received

7-PO1	A randomized controlled study of daily aspirin to reduce fibrosis progression in metabolic dysfunction-associated steatotic liver disease	Khanisorn Meesri	Received

7-PO3	Immune landscaping in a mouse model unveils an immunosuppressive cell composition in hepatic crown-like structures involved in metabolic dysfunction-associated steatohepatitis	Ainhoa Asensio Aldave	Received

7-PO5	Relationships between fibrosis status, multimorbidity, and all-cause mortality in people with metabolic-dysfunction associated steatotic liver disease in UK Biobank	Qi Feng	Received

7-PO6	Steatotic liver disease (SLD) in the adult population attending a health check-up program in Thailand: Prevalence and fibrosis status	Pimsiri Sripongpun	Received

8-PO4	Effect of diabetes treatment and antilipidemic drugs on metabolic dysfunction-associated steatotic liver disease in type 2 diabetic patients	Zülal &304;stemihan	Received

8-PO1	HK3, a novel MASH drug with profound anti-obesity action	Juergen Eckel	Received

8-PO3	Liver adrenoceptor alpha-1b plays a protective role in MASLD progression	Bernie Efole	Received

8-PO7	Impact of type 2 diabetes on hepatic fibrosis in patients with MASLD	Paula Mesquita	Received

8-PO5	Statin, but not aspirin use is inversely associated with steatotic liver disease and increased liver stiffness: Results from two large prospective population based studies	Jesse Pustjens	Received

8-PO2	Advanced metabolic-dysfunction associated steatotic liver disease fibrosis: Low number-needed-to screen in multiple lines of care	A.G. (Onno) Holleboom	Received

8-PO6	MASLD and FIB4 are independent predictors of major adverse liver outcomes and cardiovascular events in type 2 diabetes: findings from a single-center cohort using AI-driven machine learning	Valentin Calvez	Received

9-PO7	Higher cut off values of CAP is needed to avoid over diagnosis of steatosis in obese patients	Gamal Shiha	Received

9-PO5	Prevalence of low ceruloplasmin in patients with alcohol use disorder	Hanna Blaney	Received

9-PO6	Distinct postprandial metabolic and inflammatory responses in healthy individuals versus patients with metabolic dysfunction-associated steatotic liver disease	Sinéad Mullin	Received

9-PO1	The vitamin E conundrum: Should you still be using it for metabolic dysfunction-associated steatotic liver disease (MASLD)	Shweh Fern Loo	Received

9-PO4	Degree of adherence to the mediterranean diet is highly predictive of prognosis in patients with MASLD: Findings from NHANES 2011-2018	Tsubasa Tsutsumi	Received

9-PO2	Association of newly-onset dyslipidemia and metabolic dysfunction-associated steatotic liver disease (MASLD) among chronic hepatitis B patients with antivirus treatment in China	Sijia Dong	Received

9-PO3	Validation of PNPLA3 polymorphisms as risk factor for MASLD and MASH in Southeast Asian populations with MASLD	Sakkarin Chirapongsathorn	Received

10-PO4	Hepatoprotective effects of fatty acid synthase inhibitor TVB-3664 in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH	Michael Feigh	Received

10-PO3	Determining the prevalence and characterizing the associated factors and health outcomes related to Metabolic dysfunction-associated steatotic liver disease (MASLD) and Metabolic dysfunction-associated steatohepatitis (MASH) in patients with type 2 diabetes mellitus at Sultan Qaboos University Hospital: A prospective cohort study	Dalal Al-Harthi	Received

10-PO1	Clinical superior applicability and repeatability of Hepatoscope 2DTE thanks to imaging-related criteria	Cindy Serdjebi	Received

10-PO7	Nationwide Comparison of the Epidemiology of MASLD and ALD in the Entire Korean Population from 2010 to 2022	Chang-Gue Son	Received

10-PO2	A serial investigation to develop herbal-derived therapeutics targeting MASLD and metabolic syndrome using Amomum Xanthioides	Seung-Ju Hwang	Received

10-PO5	Hepatocyte-derived extracellular vesicles carrying miR-21 trigger muscle cell dysfunction	Diogo Alexandre Fernandes	Received

11-PO2	Paving the way for MASH screening of high-risk patients in primary and secondary care	Sofia Carvalhana	Received

11-PO3	Prevalence of multifactorial steatotic liver disease: Why it should be included in the international classification of steatotic liver disease	ROSANNA VILLANI	Received

11-PO5	Awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) in four cities in the United States, including among people with diabetes and primary care providers	Jeffrey V Lazarus	Received

11-PO7	Risk-stratification of patients with metabolic dysfunction-associated steatotic liver disease and indeterminate vibration-controlled transient elastography	David Marti-Aguado	Received

11-PO6	ASAP score for HCC risk stratification in patients with metabolic dysfunction-associated steatotic liver disease on long-term follow-up	Marta Guariglia	Received

11-PO4	High burden of MASLD and metALD in People with HIV: A call for liver fibrosis screening prioritization	Felice Cinque	Received

12-PO2	Metabolic associated steatotic liver disease and mental illness: role of fibroblast growth factor-21	Karen Houseknecht	Received

12-PO3	The pattern of liver enzymes enhances the prognostic value of the Fibrosis-4 index for patients with metabolic dysfunctionassociated steatotic liver disease	Emma Hajaj	Received

12-PO5	Unveiling the hidden link: Psoriasis and liver disease risk	Silvia Zanella	Received

12-PO6	Association between polycystic ovary syndrome, steatotic liver disease in pregnancy, and adverse pregnancy outcomes: results from the prospective Fatty Liver in Pregnancy cohort	Cecilia Katzenstein	Received

12-PO4	Exploring the interplay between sarcopenia, liver and cardiovascular damage in non-cirrhotic MASLD patients: a genetic perspective	Annalisa Cespiati	Received

12-PO7	Use of Glucagon-like peptide-1 receptor agonist is associated with reduced risk of major liver-related events: A meta-analysis	Ciro Celsa	Received

12-PO1	Hormetic effects of 7-Ketocholesterol in preventing ferroptosis-induced hepatocyte death	Oren Tirosh	Received

13-PO2	Assessing the impact of glucagon-like peptide-1 receptor agonists in metabolic dysfunction associated steatosis liver disease	Amreen Dinani	Received

13-PO1	Alcohol and metabolic factors influence steatotic liver disease clinical outcomes	Katrina Pekarska	Received

13-PO7	Role of genetic variants in association with the severity of liver fibrosis and steatosis in patients with steatotic liver disease	Pisit Tangkijvanich	Received

13-PO4	Risk factor awareness for liver disease in four United States cities	Jeffrey V Lazarus	Received

13-PO6	Diagnosis, prognosis and sequential use of non-invasive tests in patients with MetALD	Nikolaj Torp	Received

13-PO3	JAK2 inhibitor ruxolitinib ameliorates portal hypertension associated with metabolic dysfunction-associated liver disease	yingjie Ai	Received

14-PO1	Diagnostic performance of serum mac-2-binding protein glycosylation isomer as a fibrosis biomarker in non-obese and obese patients with steatotic liver disease	Pisit Tangkijvanich	Received

14-PO6	Fast and robust MRI assessment of abdominal obesity and liver tissue characteristics a population-scale analysis	Magdalena Nowak	Received

14-PO5	10 year progression of metabolic risk factors - correlation with steatosis and fibrosis degree in a general population cohort	Joana Estrabocha	Received

14-PO2	Effect of constitutive androstane receptor activation on hepatic unsaturated triglyceride levels	Petr Pavek	Received

14-PO7	A comparison of the prognostic value of 10 body composition markers for steatosis, MASH and fibrosis in a general population setting	Laurens van Kleef	Received

14-PO3	Arsenic as a risk factor for hepatocellular carcinoma (HCC) risk among patients with metabolic associated liver disease (MASLD)	Priya Roy	Received

15-PO2	Arsenic as a risk factor for metabolic-associated steatotic liver disease (MASLD): A mechanistic study	Priya Roy	Received

15-PO3	Low doses of bacterial D-lactate modulate liver steatosis and ameliorate experimental MASLD	André Santos	Received

15-PO5	Does cardiovascular risk differ with age-specific body composition in women with in metabolic dysfunction-associated steatotic liver disease?	Mariana Ramírez-Mejía	Received

15-PO4	From alcohol to metabolic dysfunction: a new leading cause of cirrhosis in Mexico	Nahum Méndez-Sánchez	Received

15-PO1	Anti-steatotic capacity screen for metabolic-associated steatotic liver disease therapeutics	Victoria Palasantzas	Received

16-PO2	Circulating CEACAM1 as a biomarker for hepatic steatosis in a metabolic context: Insights from the Portuguese PREVADIAB2 study	Rita Patarrão	Received

16-PO5	Prevalence and its associated risk factors of metabolic dysfunction-associated steatotic liver disease among information technology employees in India: A cross-sectional study	Bhargava Bharam	Received

16-PO7	Physics-based modeling of cholesterol and bile acids metabolism: Insights into the enterohepatic circulation and implications for metabolic dysfunction-associated steatotic liver disease (MASLD)	Flora Bahrami	Received

16-PO3	Gaps in MAFLD screening and management: a retrospective audit of patients at cardiometabolic risk in secondary care	Monica Cucco	Received

16-PO6	Volatile organic compound metabolites in urine are associated with MASLD and fibrosis: an environmental health study	Laurens van Kleef	Received

16-PO4	Purified low-fat dietary intervention does not reverse MASLD-associated cerebral hypoxia and neuroinflammation in a MASLD mouse model	Matthew Siddle	Received

17-PO5	Comparison of diagnostic accuracy and utility of non-invasive tests for clinically significant liver disease among a general population with metabolic dysfunction	Laurens van Kleef	Received

17-PO6	Alteration feature of VCAM1 in liver tissue of MASLD condition	Yong-Hwi Kang	Received

17-PO1	Measuring hepatic steatosis with proton density fat fraction quantification at 0.55T: Pilot study and comparison with 3.0T MRI	Rochelle Wong	Received

17-PO2	A human stem cell-based hepatic model as a tool for metabolic dysfunction-associated steatotic liver disease modeling and drug screening	Raquel Bozzo	Received

17-PO7	Missense variations in FADS1 and SCD1 genes oppositely affect lipid profile and cardiovascular risk in Italian children with MASLD: A possible monitoring tool also in adults?	Miriam Longo	Received

17-PO4	Role of neck circumference as a screening modality in metabolic dysfunction-associated steatotic liver disease in rural area	Varathpavee Bhuriveth	Received

18-PO1	Mapping the hepatic mtDNA genomic landscape in patients with MASLD: The era of GPT-4 artificial intelligence	Miriam Longo	Received

18-PO3	Metabolic dysfunction-associated steatotic liver disease (MASLD) in patients with inflammatory bowel disease (IBD): A single-center prospective study.	Ploutarchos Pastras	Received

18-PO6	Integrating multidisciplinary screening for HCV micro-elimination in populations with metabolic disorders: Findings from the LIVE(RO)2 Project in Romania	Liana Gheorghe	Received

18-PO5	NT-proBNP levels ?orrelate with liver fibrosis in MASLD patients	Volodymyr Cherniavskyi	Received

18-PO7	Prevalence and predictors of steatotic liver disease and significant liver fibrosis in an integrated multidisciplinary healthcare pathway model	Angelo Armandi	Received

18-PO2	Impact of hepatitis C eradication with direct-acting antivirals on metabolic and liver-related outcomes in diabetic patients: A long-term prospective analysis	Clelia Asero	Received

18-PO4	RIPK3 inhibition boosts hepatocyte energy and glucose metabolism while reducing inflammation and fibrosis under metabolic stress	Marta Afonso	Received

19-PO7	Cell-specific functions of RIPK3 in hepatocyte-macrophage communication in metabolic-dysfunction associated steatotic liver disease	Mariana Isabel Alves	Received

19-PO2	Prevalence of steatotic liver disease in people living with HIV and high prevalence of cardiovascular risk factors	Ins Pintassilgo	Received

19-PO4	Hepatic miRNA expression in experimental models of metabolic dysfunction-associated steatotic liver disease	André L. Simão	Received

19-PO6	Alcohol-induced immune-metabolic deregulation exacerbates aortic lesion progression in a novel murine model for MetALD	Constanze Hoebinger	Received

19-PO3	Bone fragility and fracture risk assessment in metabolic disfunction-associated steatotic liver disease	Clelia Asero	Received

19-PO5	Non-invasive parameters compared to FibroScan for the assessment of liver stiffness and controlled attenuation parameters in patients with fatty liver disease	Amal Joseph	Received

19-PO1	Combined mGluR5 inhibition and AMPK activation by MPEP: dual approach to reducing lipid accumulation in hepatic steatosis	Michelangelo Trucchi	Received

20-PO1	Liver fibrosis in the elderly: Prevalence and association with cognitive function in the Whitehall II study	Chengyi Ding	Received

20-PO4	The liver frailty index is a good reflection of muscle function and identifies increased frailty in patients with non-cirrhotic steatotic liver disease compared with healthy controls	Guillaume Henin	Received

20-PO2	Screening of advanced liver fibrosis and metabolic dysfunction-associated steatotic liver disease assessed by transient elastography in Roma population	Robert Nastasa	Received

20-PO5	Endoscopic ultrasonography-guided liver biopsy: A good alternative from an endohepatologist point of view	María Teresa Alvarez-Nava	Received

20-PO3	Liver stiffness measurement by SuperSonic Imagine two-dimensional shear wave elastography to predict hepatocellular carcinoma in non-cirrhotic metabolic dysfunction-associated steatotic liver disease	Madalina Gabriela Indre	Received

20-PO6	Baseline liver elastography and its longitudinal changes predict liver related outcomes in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)	Lucrezia Petrucci	Received

20-PO7	Bile acids as potential metabolic markers to differentiate progression and resolution of metabolic dysfunction-associated steatohepatitis	Simon Isfort	Received

21-PO6	Communication through gut-derived extracellular vesicles: Implications for liver disease progression	Rita Machado de Oliveira	Received

21-PO2	Lifestyle modification and cognitive behavioral therapy in the treatment of MASLD	Vaclav Smid	Received

21-PO7	The major importance of a multidisciplinary team to manage patients with a multifactorial disease such as steatotic liver disease	Sergio Bronze	Received

21-PO5	Serological biomarkers of the extracellular matrix reflecting fibroblast activity and endothelial damage are elevated in patients at risk of MASH with significant liver stiffness	Diana Julie Leeming	Received

21-PO1	Minibioreactor arrays (MBRAs) to model microbiome response to tryptophan and alcohol in the context of alcohol-associated liver disease (ALD)	ciocan dragos	Received

21-PO3	Comparative analysis of prevalence, metabolic profiles, and socio-demographic characteristics of MetALD, MASLD, and ALD in a rural area	Varathpavee Bhuriveth	Received

22-PO4	Severe metabolic dysfunction-associated steatotic liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota in people with HIV	Riccardo Righetti	Received

22-PO6	Multi-parametric MRI of the liver and heart are associated with major liver and cardiovascular events: A prospective cohort study	Edward Jackson	Received

22-PO7	Non-invasive assessment of liver fat fraction utilizing the electrical properties of tissue	Michael Thornton	Received

22-PO3	Determinants of liver stiffness improvements and worsening in metabolic dysfunction associated steatotic liver disease: Insights from two cohorts	Mirko Zoncapè	Received

22-PO1	ALD is diagnosed at more advanced stages of fibrosis compared to MetALD and MASLD in the general population	Jordi Gratacós-Ginès	Received

22-PO2	Natural history of metabolic dysfunction-associated steatotic liver disease: A 5-year community-based follow-up study	Julia Uhanova	Received

22-PO5	RIPK3 modulates the liver immune microenvironment during MASLD progression towards hepatocellular carcinoma	André Cardador	Received

23-PO7	Dynamic changes in liver stiffness independently predict liver-related event risk in metabolic dysfunction-associated steatotic liver disease	Isabel Veloso Alves Pereira	Received

23-PO4	Targeted lipidomics and fatty acids profiles reveal w-oxidation as a rescue pathway of inhibited -oxidation in a rat model of drug-associated microvesicular liver steatosis	Margarida Silva	Received

23-PO3	Prognostic significance of ELF test compared to liver elastography and liver biopsy in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)	Antonio Liguori	Received

23-PO1	Impact of a multidisciplinary clinic for metabolic dysfunction-associated steatotic liver disease on cardiovascular risk and liver health	Mirko Zoncapè	Received

23-PO6	Prevalence, reference ranges and determinants of hepatic steatosis and increased liver stiffness in the third trimester of pregnancy using transient elastography	Luiza Borges Manna	Received

23-PO2	Novel point-of-care, rapid breath test to identify subjects with metabolic-dysfunction associated steatotic liver disease with advanced fibrosis - a pilot study	Osnat Sella Tavor	Received

23-PO5	Prevalence of liver fibrosis in vulnerable individuals from North-Eastern Romania using Transient Elastography	Ermina Stratina	Received

24-PO6	The impact of COVID - 19 on liver fibrosis progression in mexican patients with metabolic dysfunction associated steatotic liver disease: a case - control study	Miriam Gabriela Reyes Zermeño	Received

24-PO5	Liver fibrosis in T2DM, prevalence and feasibility of screening with AI in primary care	Jude Oben	Received

24-PO3	Dynamic change in the enhanced liver fibrosis test to predict adverse outcomes in chronic liver disease	YAEL MILGROM	Received

24-PO4	Bariatric surgical interventions in steatotic liver disease (SLD): Mapping global research trends of the last two decades (2005-2024)	Mobin Ibne Mokbul	Received

24-PO7	Enhancing detection of significant fibrosis in people living with HIV: revisiting the conventional ALT cut-off	Ahmed Kamel	Received

24-PO1	Computational electrophysiology highlights cardiac toxicity risks of Pentoxifylline, a key therapy for fatty liver disease, via sodium current inhibition	Chitaranjan Mahapatra	Received

SLD Summit 2025

23-25 January, Estoril

About us

Search and consult posters online
in an exclusive section
for each poster

ACTIVE FROM 23/01/2025 TO 23/01/2025

Poster
Gallery

Upload
Poster

Featured Poster

Vote poster

Poster Discussion
Forum



		Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.

About us

Terms and Conditions

Special Access

Commercial Web Access